Site Searches
1 search
| Search | Protocol | Status | Sites | Owner | Last run | Actions |
|---|---|---|---|---|---|---|
CDK4/6 Inhibitor — HR+/HER2− Metastatic Breast Cancer (Phase 3) US oncology sites with CDK4/6 inhibitor trial experience in HR+/HER2− metastatic breast cancer, weighted toward centers active in older-adult populations. | NCT06377852 Ryght Demo | Complete | 158 / 1801 Target: 158 Tier 1 | You 1 run | v1 · 2026-05-06 |